Company / SG&A Expense
Edesa Biotech, Inc. SG&A Expense History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$3.4M
FY2021
5-year range
$2.0M / $3.4M
FY2017-FY2021
Trend
+65.4%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense returned to growth in FY2021 after 2 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2021 with a 5-year CAGR of +3.3%.
Increased from $3M to $3M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +4.7%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2021, sg&a expense increased 65.4% year-over-year.
- Peak sg&a expense was recorded in FY2014.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $3.4M | +65.4% |
| FY2020 | $2.0M | -30.5% |
| FY2018 | $2.9M | -8.8% |
| FY2017 | $3.2M | +12.4% |
| FY2016 | $2.9M | +62.2% |
| FY2015 | $1.8M | -51.6% |
| FY2014 | $3.7M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026